Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs
The DOI matches its Crossref record.
Abstract
Twenty-six healthy subjects from 19 to 85 yr old took single 15-mg doses of flurazepam (FLZ). Concentrations of desalkylfurazepam (DAFLZ), its principal metabolite, were measured by gas-liquid chromatography in multiple samples drawn 7 or more days after the dose. For the first 6 to 8 hr after drug, several additional FLZ metabolites appeared in plasma, but only DAFLZ was detected from 12 hr onward. Its elimination half-life (t1/2) (range, 37 to 289 hr) was longer in elderly than in young men (mean 74 and 160 hr, p less than 0.05), but t1/2 in young and elderly women was much the same (90 and 120 hr, P = NS). Eighteen of the 26 subjects then received FLZ, 15 mg, nightly for 15 consecutive nights. Blood samples were drawn during FLZ dosage and in the withdrawal period, and morning self-ratings of mood and sleep patterns were obtained using visual analogue scales. DAFLZ cumulation was extensive, with a mean cumulation ratio of 7.5. Mean steady-state plasma levels of DAFLZ were higher in elderly than in young men (81 and 53 ng/ml, P less than 0.05), but values were essentially the same in elderly and young women (85 and 86 ng/ml). Single-dose t1/2 correlated with washout t1/2 after termination of FLZ treatment (r = 0.87, P less than 0.01). Clinical self-ratings indicated increases over time in perception of morning sedation; changes slowly reverted to baseline in the week after dosage. Sleep patterns also improved on FLZ (shortened latency, longer duration, "deeper" sleep). After termination of treatment, sleep parameters returned to baseline with a suggestion of "overshoot" sleep disturbance at days 5 and 7 after drug. There was no evidence of increased sensitivity to FLZ in the elderly. Subjects did not perceive any impairment of intellectual function or motor performance, and no other adverse reactions were reported.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Human serum albumin: From bench to bedside
Fanali, G., di Masi, A., Trezza, V., Marino, M., Fasano, M., & Ascenzi, P. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.12.002 · Cited by 1,931
Mangoni, A. A., & Jackson, S. H. D. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.02007.x · Cited by 1,874
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Greenblatt (1982) · doi:10.1056/nejm198205063061804 · Cited by 584
Current Status of Benzodiazepines
Koch-Weser, J., Greenblatt, D. J., Shader, R. I., & Abernethy, D. R. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308183090705 · Cited by 451
Self-citationManagement of drug therapy in the elderly
Desforges, J. F., Montamat, S. C., Cusack, B. J., & Vestal, R. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908033210507 · Cited by 388
Desforges, J. F., Prinz, P. N., Vitiello, M. V., Raskind, M. A., & Thorpy, M. J. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008233230805 · Cited by 318
The Ambiguous Relation between Aging and Adverse Drug Reactions
Gurwitz, J. H., & Avorn, J. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-11-956 · Cited by 313
Joining the DoTS: new approach to classifying adverse drug reactions
Aronson, J. K., & Ferner, R. E. (2003) · BMJ · doi:10.1136/bmj.327.7425.1222 · Cited by 297
Sensitivity to triazolam in the elderly
Greenblatt, D. J., Harmatz, J. S., Shapiro, L., Engelhardt, N., Gouthro, T. A., & Shader, R. I. (1991) · New England Journal of Medicine · doi:10.1056/nejm199106133242403 · Cited by 258
Self-citationThe Diagnosis and Management of Insomnia
Oates, J. A., Wood, A. J. J., Gillin, J. C., & Byerley, W. F. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001253220406 · Cited by 219
Pierce, M. W., & Shu, V. S. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90279-m · Cited by 174
Avorn, J., Gurwitz, J. H., & Rochon, P. (2006) · Geriatric Medicine · doi:10.1007/0-387-22621-4_7 · Cited by 165
Early Morning Insomnia with Rapidly Eliminated Benzodiazepines
Kales, A., Soldatos, C. R., Bixler, E. O., & Kales, J. D. (1983) · Science · doi:10.1126/science.6131538 · Cited by 138
Olubodun, J. O., Ochs, H. R., Von Moltke, L. L., Roubenoff, R., Hesse, L. M., Harmatz, J. S., Shader, R. I., & Greenblatt, D. J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2003.01852.x · Cited by 104
Self-citationImplications of Altered Drug Disposition in the Elderly: Studies of Benzodiazepines
Greenblatt, D. J., Shader, R. I., & Harmatz, J. S. (1989) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1989.tb03246.x · Cited by 102
Self-citationEffect of Gradual Withdrawal on the Rebound Sleep Disorder after Discontinuation of Triazolam
Greenblatt, D. J., Harmatz, J. S., Zinny, M. A., & Shader, R. I. (1987) · New England Journal of Medicine · doi:10.1056/nejm198709173171202 · Cited by 96
Self-citationNighttime and daytime efficacy of flurazepam and oxazepam in chronic insomnia
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.2.191 · Cited by 33
Self-citation
Metadata
- Authors
- Greenblatt, D. J., Divoll, M., Harmatz, J. S., MacLaughlin, D. S., & Shader, R. I.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1981-10
- Volume
- 30
- Issue
- 4
- Pages
- 475-486
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1965672832
- Cited by
- 150
- References
- 0
- FWCI
- 14.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.